AGEN1181, AN FC-ENHANCED ANTI-CTLA-4 ANTIBODY, ALONE AND IN COMBINATION WITH BALSTILIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL PHASE I RESULTS

被引：5
|
作者：
El-Khoueiry, Anthony [1 ]
Bullock, Andrea [2 ]
Tsimberidou, Apostolia [3 ]
Mahadevan, Daruka [4 ]
Wilky, Breelyn [5 ]
Twardowski, Przemyslaw [6 ]
Bockorny, Bruno
Moser, Justin [7 ]
Feliu, Waldo Ortuzar [8 ]
Grossman, Joseph [8 ]
Rosenthal, Katherine [8 ]
O'Day, Steven [8 ]
Gordon, Michael [7 ]
机构：
[1] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] MD Anderson Canc Ctr, Houston, TX USA
[4] UT Hlth Sci Ctr San Antonio, San Antonio, TX USA
[5] Univ Colorado, Ctr Canc, Aurora, CO USA
[6] St Johns Canc Inst, Santa Monica, CA USA
[7] HonorHlth Res Inst, Scottsdale, AZ USA
[8] Agenus Inc, Lexington, MA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.479
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
479
引用
收藏
页码：A509 / A509
页数：1
相关论文
共 50 条
  • [1] AGEN1181, AN FC ENGINEERED ANTI-CTLA-4 ANTIBODY, DEMONSTRATES CLINICAL ACTIVITY, ALONE OR IN COMBINATION WITH BALSTILIMAB (ANTI-PD-1), AND BROADENS THE THERAPEUTIC POTENTIAL OF CTLA-4 THERAPY
    O'Day, Steven
    El Khoueiry, Anthony
    Ramamurthy, Chethan
    Bullock, Andrea
    Shapiro, Irina
    Serina
    Han, Haiyong
    Namagerdi, Lernik Ohanjanian
    Kaleta, Remigiusz
    Wijatyk, Anna
    Wijatyk, Olivia
    Ortuzar, Waldo
    Ancukiewicz, Marek
    Buell, Jennifer
    Chand, Dhan
    Gordon, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A242 - A242
  • [2] Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimab.
    Shapiro, Irina
    Lim, Min
    Pabla, Simarjot
    O'Day, Steven J.
    El-Khoueiry, Anthony
    Ramamurthy, Chethan
    Bullock, Andrea J.
    Gordon, Michael S.
    Buell, Jennifer
    Chand, Dhan
    Wijatyk, Anna
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Fc-enhanced anti-CTLA-4 antibody, AGEN1181: new mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumors.
    Tanne, Antoine J.
    Galand, Claire
    Abou-Slaybi, Abdo
    Wilkens, Margaret
    Marques, Marilyn
    Ng, Serina
    Han, Haiyong
    Dietrich, Sylvia
    Waight, Jeremy
    Joshi, Bishnu
    Yigit, Burcu
    Michelet, Xavier
    Levey, Daniel
    Savitsky, David
    Buell, Jennifer
    Chand, Dhan
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
    da Silva, Ines Pires
    Li, Isabel
    Ugurel, Selma
    Serra-Bellver, Patricio
    Andhale, Avanti
    Burnette, Hannah
    Aya, Francisco
    Conway, Jordan W.
    Braden, Jorja
    Carlino, Matteo S.
    Menzies, Alexander M.
    Weichenthal, Michael
    Mohr, Peter
    Gutzmer, Ralf
    Arance, Ana M.
    Johnson, Douglas B.
    Lorigan, Paul
    Schadendorf, Dirk
    Lo, Serigne N.
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2024, 205
  • [5] AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.
    O'Day, Steven
    Ramamurthy, Chethan
    Bullock, Andrea J.
    El-Khoueiry, Anthony B.
    Ohanjanian, Lernik
    Wijatyk, Anna
    Feliu, Waldo Ignacio Ortuzar
    Shapiro, Irina
    Ancukiewicz, Marek
    Chand, Dhan
    Buell, Jennifer
    Gordon, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies.
    Waight, Jeremy
    Manrique, Mariana
    Gombos, Randi
    Costa, Matthew
    Iyer, Priyadarshini
    Vincent, Sylvia
    Ward, Rebecca
    Paltrinieri, Elena
    Chand, Dhan
    Wilson, Nicholas
    Buell, Jennifer
    Savitsky, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    Boutros, Celine
    Tarhini, Ahmad
    Routier, Emilie
    Lambotte, Olivier
    Ladurie, Francois Leroy
    Carbonnel, Franck
    Izzeddine, Hassane
    Marabelle, Aurelien
    Champiat, Stephane
    Berdelou, Armandine
    Lanoy, Emilie
    Texier, Matthieu
    Libenciuc, Cristina
    Eggermont, Alexander M. M.
    Soria, Jean-Charles
    Mateus, Christine
    Robert, Caroline
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 473 - 486
  • [8] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    Celine Boutros
    Ahmad Tarhini
    Emilie Routier
    Olivier Lambotte
    Francois Leroy Ladurie
    Franck Carbonnel
    Hassane Izzeddine
    Aurelien Marabelle
    Stephane Champiat
    Armandine Berdelou
    Emilie Lanoy
    Matthieu Texier
    Cristina Libenciuc
    Alexander M. M. Eggermont
    Jean-Charles Soria
    Christine Mateus
    Caroline Robert
    Nature Reviews Clinical Oncology, 2016, 13 : 473 - 486
  • [9] Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody ®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors
    Li, Daneng
    Sharma, Sunil
    She, Kristine
    Li, Wenda
    Li, Ai
    Zheng, Songmao
    Liu, Guizhong
    Ndukwo, Ogon
    Hu-Lowe, Dana
    Chisamore, Michael
    Luo, Peter
    Zha, Jiping
    Patel, Manish R.
    CANCER RESEARCH, 2023, 83 (08)
  • [10] Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors
    Perez-Santos, Martin
    PHARMACEUTICAL PATENT ANALYST, 2020, 9 (05) : 149 - 154
12345